Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hrzenjak, A; Moinfar, F; Kremser, ML; Strohmeier, B; Staber, PB; Zatloukal, K; Denk, H.
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells.
Mol Cancer Ther. 2006; 5(9):2203-2210
Doi: 10.1158/1535-7163.MCT-05-0480
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Hrzenjak Andelko
- Co-Autor*innen der Med Uni Graz
- Denk Helmut
- Moinfar Farid
- Staber Philipp
- Zatloukal Kurt
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Covalent modifications of histone proteins, in particular deacetylation of lysine residues, are important for the regulation of gene transcription both in normal and malignant cells. These processes are controlled by histone acetyltransferases and histone deacetylases (HDAC) and have up to now not been described in solid mesenchymal tumors. The present study shows differences in the HDAC1 and HDAC2 expression in endometrial stromal sarcomas (ESS) and a cognate cell line (ESS-1) compared with nonneoplastic endometrial stroma. We show for the first time that HDAC2 expression is consistently increased in ESS. In contrast, HDAC1 expression is generally lower than HDAC2 both in nonneoplastic stroma and in ESS, suggesting that these two proteins, although closely related, are regulated in different ways. In vitro experiments with an ESS cell line showed that valproate, an inhibitor of the class I HDACs, led to significant HDAC2 decrease and to cell differentiation. HDAC2 inhibition in ESS-1 cells caused significant changes in the cell cycle by inhibiting G1-S transition and influencing expression of p21WAF1 and cyclin D1. Moreover, in ESS-1 cells, increased expression of the p21WAF1 was associated with reduction of HDAC2 expression after transfection with small interfering RNA directed against HDAC2. Our results suggest that HDAC2 might be considered as potential drug target in the therapy of ESS and that HDAC inhibitors should be further evaluated in clinical trials in ESS.
- Find related publications in this database (using NLM MeSH Indexing)
- Cell Differentiation - drug effects
- Cell Growth Processes - drug effects
- Cyclin-Dependent Kinase Inhibitor p21 - biosynthesis Cyclin-Dependent Kinase Inhibitor p21 - genetics
- Endometrial Neoplasms - drug therapy Endometrial Neoplasms - enzymology Endometrial Neoplasms - genetics Endometrial Neoplasms - pathology
- Female -
- Histone Deacetylase 1 -
- Histone Deacetylase 2 -
- Histone Deacetylase Inhibitors -
- Histone Deacetylases - biosynthesis Histone Deacetylases - genetics
- Humans -
- Immunohistochemistry -
- RNA, Small Interfering - genetics
- Repressor Proteins - antagonists and inhibitors Repressor Proteins - biosynthesis Repressor Proteins - genetics
- Sarcoma, Endometrial Stromal - drug therapy Sarcoma, Endometrial Stromal - enzymology Sarcoma, Endometrial Stromal - genetics Sarcoma, Endometrial Stromal - pathology
- Tumor Cells, Cultured -
- Valproic Acid - pharmacology